Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, and Johnson & Johnson. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$878.09 +7.72 (+0.89%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$878.90 +0.81 (+0.09%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The stock has a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards its future performance.
  • Recent trading activity shows the stock price at $827.41, reflecting a significant increase of $16.98 in a single day, which may suggest strong market interest.
  • Eli Lilly and Co has announced a quarterly dividend increase to $1.50, up from $1.30, which represents a yield of 0.73%. This increase can attract income-focused investors.

Cons of Eli Lilly and Company

  • The stock has a high P/E ratio of 89.45, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • The company has a debt-to-equity ratio of 2.03, suggesting that it relies heavily on debt financing, which can be risky if market conditions change.
  • Insider ownership is low at 0.13%, which may indicate a lack of confidence from those within the company regarding its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$826.26 billion
P/E Ratio
74.99
Consensus Rating
Moderate Buy
Consensus Price Target
$997.50 (+13.6% Upside)
Volume
4.42 million shares
Average Volume
4.06 million shares
Today's Range
$869.62
$889.36
50-Day Range
$726.24
$878.09
52-Week Range
$711.40
$972.53
Dividend Yield
0.60%
UnitedHealth Group stock logo

2. UnitedHealth Group NYSE:UNH

$526.68 -3.36 (-0.63%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$527.26 +0.58 (+0.11%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company reported a strong quarterly earnings per share (EPS) of $6.81, exceeding analysts' expectations, indicating robust financial performance and effective management.
  • UnitedHealth Group has a solid market capitalization of $501.63 billion, reflecting its significant presence and stability in the healthcare sector.
  • The stock is currently trading at approximately $550, which is below its one-year high of $630.73, suggesting potential for price appreciation as it approaches previous highs.

Cons of UnitedHealth Group

  • The stock has a relatively high price-to-earnings (P/E) ratio of 35.17, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • UnitedHealth Group's current ratio of 0.83 suggests that the company may have liquidity issues, as it indicates that current liabilities exceed current assets.
  • Analysts have recently adjusted their price targets downward, with Barclays lowering their target from $655 to $642, which may reflect concerns about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$487.79 billion
P/E Ratio
33.98
Consensus Rating
Buy
Consensus Price Target
$629.32 (+19.5% Upside)
Volume
3.34 million shares
Average Volume
4.35 million shares
Today's Range
$525.39
$532.39
50-Day Range
$485.52
$610.63
52-Week Range
$436.38
$630.73
Dividend Yield
1.58%
Novo Nordisk A/S stock logo

3. Novo Nordisk A/S NYSE:NVO

$86.39 -0.78 (-0.90%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$86.04 -0.35 (-0.41%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent upgrades from multiple analysts, including a "strong-buy" rating from BNP Paribas, indicate strong market confidence in Novo Nordisk's future performance.
  • The stock has a consensus target price of $145.25, suggesting significant upside potential from its current trading price of $82.64.
  • Institutional investors have shown increased interest, with DAVENPORT & Co LLC boosting its holdings by 75.1%, reflecting confidence in the company's growth prospects.

Cons of Novo Nordisk A/S

  • The stock has recently experienced a decline of 2.1%, which may raise concerns about short-term volatility and market sentiment.
  • With a PE ratio of 26.74, the stock may be considered overvalued compared to industry peers, potentially limiting future price appreciation.
  • The company has a quick ratio of 0.75, which is below 1, indicating potential liquidity issues in meeting short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$391.18 billion
P/E Ratio
26.26
Consensus Rating
Buy
Consensus Price Target
$145.25 (+68.1% Upside)
Volume
8.70 million shares
Average Volume
9.60 million shares
Today's Range
$86.14
$88.77
50-Day Range
$78.74
$111.69
52-Week Range
$78.17
$148.15
Dividend Yield
0.83%
Johnson & Johnson stock logo

4. Johnson & Johnson NYSE:JNJ

$153.10 -0.41 (-0.27%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$153.64 +0.54 (+0.35%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson reported earnings per share (EPS) of $2.04 for the latest quarter, exceeding the consensus estimate of $1.99, indicating strong financial performance and effective management.
  • The company has a robust return on equity of 34.35%, which suggests that it is efficient in generating profits from its equity investments, making it an attractive option for investors seeking high returns.
  • With a quarterly revenue of $22.52 billion, which is up 5.3% year-over-year, Johnson & Johnson demonstrates consistent growth, appealing to growth-oriented investors.

Cons of Johnson & Johnson

  • The company’s EPS has decreased from $2.29 in the same quarter last year to $2.04, indicating a decline in profitability, which may concern potential investors.
  • Johnson & Johnson's payout ratio is currently 74.59%, suggesting that a significant portion of its earnings is being distributed as dividends, which could limit funds available for reinvestment in growth opportunities.
  • Analysts have mixed ratings on the stock, with some lowering their price targets, which may indicate uncertainty about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$369.59 billion
P/E Ratio
23.02
Consensus Rating
Moderate Buy
Consensus Price Target
$170.67 (+11.5% Upside)
Volume
6.20 million shares
Average Volume
9.30 million shares
Today's Range
$152.80
$154.49
50-Day Range
$142.07
$154.80
52-Week Range
$140.68
$168.85
Dividend Yield
3.23%
AbbVie stock logo

5. AbbVie NYSE:ABBV

$190.67 -2.30 (-1.19%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$191.05 +0.38 (+0.20%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has a strong market capitalization of $335.60 billion, indicating a robust financial position and potential for growth.
  • The company reported a return on equity of 257.91%, showcasing its ability to generate significant profit from shareholders' equity, which is a positive indicator for investors.
  • AbbVie has a current stock price around $172.24, which is below its 52-week high of $207.32, suggesting potential for price appreciation.

Cons of AbbVie

  • AbbVie has a high debt-to-equity ratio of 9.64, which suggests that the company is heavily reliant on debt financing, potentially increasing financial risk.
  • The company missed its earnings per share estimate by $0.82, reporting $2.16 instead of the expected $2.98, which may raise concerns about its profitability.
  • AbbVie has a quick ratio of 0.54, indicating that it may struggle to meet short-term liabilities without selling inventory, which could be a red flag for liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$336.82 billion
P/E Ratio
79.45
Consensus Rating
Moderate Buy
Consensus Price Target
$208.35 (+9.3% Upside)
Volume
3.81 million shares
Average Volume
6.37 million shares
Today's Range
$190.44
$193.86
50-Day Range
$169.19
$192.95
52-Week Range
$153.58
$207.32
Dividend Yield
3.44%
AstraZeneca stock logo

6. AstraZeneca NASDAQ:AZN

$71.99 -0.37 (-0.51%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$72.60 +0.61 (+0.85%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • AstraZeneca reported a strong quarterly EPS of $1.04, exceeding expectations, which indicates robust financial performance and effective management.
  • The company achieved a revenue of $13.57 billion, surpassing analyst predictions, showcasing its ability to generate significant sales growth.
  • With a market cap of $211.49 billion, AstraZeneca is positioned as a major player in the biopharmaceutical industry, which can provide stability and growth potential for investors.

Cons of AstraZeneca

  • The company has a P/E ratio of 32.63, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • AstraZeneca's current ratio of 0.93 indicates that it may have difficulty meeting short-term liabilities, which could raise concerns about liquidity.
  • Institutional ownership is at 20.35%, which may indicate a lack of confidence from larger investors, potentially affecting stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$224.40 billion
P/E Ratio
31.85
Consensus Rating
Buy
Consensus Price Target
$89.75 (+24.7% Upside)
Volume
6.22 million shares
Average Volume
5.16 million shares
Today's Range
$71.78
$72.70
50-Day Range
$64.44
$72.36
52-Week Range
$60.47
$87.68
Dividend Yield
1.35%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$129.11 +0.89 (+0.69%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$129.02 -0.09 (-0.07%)
As of 09:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories has received an "overweight" rating from Barclays, indicating strong confidence in the stock's potential for growth, with a target price of $158.00, suggesting a potential upside of 22% from the current price.
  • The stock is currently trading at $129.51, reflecting a recent increase of 3.6%, which may indicate positive market sentiment and momentum.
  • Abbott Laboratories has a solid market capitalization of approximately $224.63 billion, which signifies its stability and ability to withstand market fluctuations.

Cons of Abbott Laboratories

  • Despite the positive outlook, the stock has a relatively high P/E ratio of 16.93, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • The company has a beta of 0.73, suggesting lower volatility compared to the market, which may limit potential high returns for investors seeking aggressive growth.
  • Abbott Laboratories has a debt-to-equity ratio of 0.32, which, while relatively low, indicates that the company is not heavily leveraged, potentially limiting its ability to finance aggressive growth strategies through debt.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$223.93 billion
P/E Ratio
16.88
Consensus Rating
Moderate Buy
Consensus Price Target
$133.06 (+3.1% Upside)
Volume
6.45 million shares
Average Volume
7.48 million shares
Today's Range
$128.07
$129.49
50-Day Range
$110.96
$132.07
52-Week Range
$99.71
$132.50
Dividend Yield
1.84%
Merck & Co., Inc. stock logo

8. Merck & Co., Inc. NYSE:MRK

$87.26 -0.79 (-0.90%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$87.04 -0.21 (-0.25%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has a strong institutional ownership, with 76.07% of its stock held by institutional investors, indicating confidence in the company's long-term performance.
  • The stock is currently trading at $90.99, which may present a buying opportunity for investors looking for value, especially considering its one-year high of $134.63.
  • Recent analyst ratings show a consensus of "Moderate Buy" with an average target price of $122.67, suggesting potential upside for investors.

Cons of Merck & Co., Inc.

  • Merck's stock has recently experienced volatility, trading down 8.8% in a single day, which may raise concerns about short-term performance.
  • Analysts have adjusted price targets downward, with Citigroup lowering its target from $130.00 to $125.00, indicating potential challenges in meeting previous expectations.
  • There is a sell rating from one analyst, which could signal caution for investors considering entering or holding a position in Merck.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$222.73 billion
P/E Ratio
12.97
Consensus Rating
Moderate Buy
Consensus Price Target
$119.06 (+36.4% Upside)
Volume
15.81 million shares
Average Volume
14.16 million shares
Today's Range
$87.12
$88.60
50-Day Range
$87.26
$103.79
52-Week Range
$87.12
$134.63
Dividend Yield
3.68%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$571.44 -1.27 (-0.22%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$567.82 -3.63 (-0.63%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is $584.38, which is near its 12-month high of $627.88, indicating strong market performance and potential for growth.
  • Thermo Fisher Scientific Inc. has a consensus rating of "Moderate Buy" from analysts, suggesting positive sentiment and confidence in the company's future performance.
  • The company recently announced a $4.00 billion stock repurchase plan, which typically signals that management believes the stock is undervalued and can enhance shareholder value.

Cons of Thermo Fisher Scientific

  • The stock has experienced insider selling, with the CEO selling 10,000 shares recently, which may raise concerns about the company's future prospects from a leadership perspective.
  • Despite a strong market capitalization of $223.52 billion, the company has a relatively high P/E ratio of 36.64, which could indicate that the stock is overvalued compared to its earnings.
  • The company has a beta of 0.76, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$219.06 billion
P/E Ratio
34.57
Consensus Rating
Moderate Buy
Consensus Price Target
$658.00 (+15.1% Upside)
Volume
1.83 million shares
Average Volume
2.05 million shares
Today's Range
$566.45
$577.48
50-Day Range
$516.18
$607.06
52-Week Range
$493.30
$627.88
Dividend Yield
0.27%
Novartis stock logo

10. Novartis NYSE:NVS

$106.17 -0.81 (-0.76%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$106.88 +0.71 (+0.67%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Recent stock performance shows resilience, with shares trading at $103.37, indicating a stable investment opportunity amidst market fluctuations.
  • Analysts have set a consensus price target of $123.38, suggesting potential upside for investors based on current valuations.
  • Institutional interest is strong, with 13.12% of the stock owned by institutional investors and hedge funds, indicating confidence in the company's future performance.

Cons of Novartis

  • Some analysts have issued sell ratings, with two research analysts rating the stock as a sell, indicating concerns about its future performance.
  • HSBC recently downgraded Novartis from a "hold" to a "reduce" rating, suggesting that the stock may not perform as well as expected in the near term.
  • The stock has experienced a 1-year high of $120.92, which may indicate that it is nearing its peak, potentially limiting future gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.67 billion
P/E Ratio
18.06
Consensus Rating
Reduce
Consensus Price Target
$123.38 (+16.2% Upside)
Volume
1.99 million shares
Average Volume
2.04 million shares
Today's Range
$106.00
$107.37
50-Day Range
$96.77
$109.84
52-Week Range
$92.35
$120.92
Dividend Yield
2.27%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$582.98 -5.52 (-0.94%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$591.78 +8.80 (+1.51%)
As of 09:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The stock is currently trading at $574.14, reflecting strong market interest and potential for growth.
  • Recent analyst upgrades have increased target prices significantly, with JPMorgan raising their target from $575.00 to $675.00, indicating strong confidence in the company's future performance.
  • Intuitive Surgical, Inc. has a robust market capitalization of $204.50 billion, suggesting a stable and established presence in the healthcare sector.

Cons of Intuitive Surgical

  • Insider selling has been notable, with CEO Gary S. Guthart selling 18,151 shares, representing a 42.84% decrease in his ownership, which may raise concerns about the company's future prospects.
  • The stock has a high price-to-earnings (P/E) ratio of 92.31, indicating that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Insiders have sold a total of 46,900 shares worth $24,590,472 over the last three months, suggesting a lack of confidence among those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$209.61 billion
P/E Ratio
90.95
Consensus Rating
Moderate Buy
Consensus Price Target
$613.10 (+5.2% Upside)
Volume
1.06 million shares
Average Volume
1.98 million shares
Today's Range
$582.16
$594.08
50-Day Range
$521.96
$610.45
52-Week Range
$364.17
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$293.54 -4.24 (-1.42%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$294.77 +1.23 (+0.42%)
As of 09:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. recently reported earnings of $5.58 per share, exceeding the consensus estimate of $5.11, indicating strong financial performance and effective management.
  • The company has shown significant revenue growth, with a year-over-year increase of 23.2%, reflecting its ability to expand its market presence and product offerings.
  • Amgen Inc. has announced a quarterly dividend increase to $2.38 per share, up from $2.25, which demonstrates a commitment to returning value to shareholders and suggests financial stability.

Cons of Amgen

  • Amgen Inc. has a high debt-to-equity ratio of 7.55, which may indicate financial risk as it suggests the company relies heavily on debt financing compared to equity.
  • The company's payout ratio is currently at 115.24%, meaning it pays out more in dividends than it earns in net income, which could be unsustainable in the long term.
  • Despite recent growth, the stock has experienced volatility, with a beta of 0.56, indicating that it may not respond strongly to market movements, which could limit potential gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$160.07 billion
P/E Ratio
38.88
Consensus Rating
Hold
Consensus Price Target
$314.09 (+7.0% Upside)
Volume
3.39 million shares
Average Volume
3.20 million shares
Today's Range
$292.58
$299.61
50-Day Range
$258.59
$307.81
52-Week Range
$253.30
$346.85
Dividend Yield
3.02%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$105.33 +0.31 (+0.30%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$105.77 +0.44 (+0.42%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The stock has recently been upgraded by multiple analysts, with Piper Sandler raising its target price from $95.00 to $115.00, indicating strong confidence in the company's growth potential.
  • Boston Scientific Co. is currently trading at approximately $103.36, which reflects a significant increase from its 12-month low of $64.08, showcasing a strong recovery and upward momentum.
  • Analysts have issued a majority of "buy" ratings for the stock, with an average target price of $100.39, suggesting that many believe the stock is undervalued and has room for growth.

Cons of Boston Scientific

  • The stock has a high price-to-earnings (P/E) ratio of 85.40, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been observed, with executives selling shares worth over $2.7 million recently, which could signal a lack of confidence in the company's short-term performance.
  • The company has a relatively low debt-to-equity ratio of 0.44, which is generally positive, but it may also indicate that the company is not leveraging debt to fuel growth as aggressively as some investors might prefer.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$155.12 billion
P/E Ratio
84.26
Consensus Rating
Buy
Consensus Price Target
$107.39 (+2.0% Upside)
Volume
5.54 million shares
Average Volume
6.18 million shares
Today's Range
$104.29
$105.92
50-Day Range
$88.03
$105.33
52-Week Range
$64.39
$107.17
Dividend Yield
N/A
Danaher stock logo

14. Danaher NYSE:DHR

$206.92 -3.09 (-1.47%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$207.68 +0.76 (+0.37%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. has a strong dividend payout ratio of 20.61%, indicating a commitment to returning value to shareholders while still retaining a significant portion of earnings for growth.
  • The stock is currently trading at $223.12, which presents a potential buying opportunity given the analysts' target prices, with some estimates suggesting a significant upside from this level.
  • Recent analyst ratings show a consensus of "Moderate Buy," with 16 analysts giving buy ratings, reflecting positive sentiment and confidence in the company's future performance.

Cons of Danaher

  • Recent price target reductions by analysts, including a cut from Jefferies Financial Group to $260.00, may indicate concerns about the company's near-term performance and market conditions.
  • The stock has experienced volatility, with a one-year low of $223.00, suggesting potential risks for investors who may be sensitive to price fluctuations.
  • Danaher Co. has a relatively high P/E ratio of 42.58, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a correction if earnings do not meet expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.69 billion
P/E Ratio
39.19
Consensus Rating
Moderate Buy
Consensus Price Target
$278.00 (+34.4% Upside)
Volume
5.23 million shares
Average Volume
4.11 million shares
Today's Range
$205.79
$210.79
50-Day Range
$206.92
$250.51
52-Week Range
$205.79
$281.70
Dividend Yield
0.51%
Stryker stock logo

15. Stryker NYSE:SYK

$391.42 -4.65 (-1.17%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$391.49 +0.07 (+0.02%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. recently reported earnings per share of $4.01, surpassing analysts' expectations of $3.87, indicating strong financial performance and growth potential.
  • The stock has a current price of $392.46, which is close to its 52-week high of $406.19, suggesting that it is performing well in the market.
  • Analysts have raised their price targets for Stryker Co., with Royal Bank of Canada increasing its target to $435.00, reflecting positive sentiment and potential for further appreciation.

Cons of Stryker

  • The stock has a high P/E ratio of 41.91, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite recent positive earnings, the company has a PEG ratio of 2.68, suggesting that its growth may not justify its current valuation, which could deter value-focused investors.
  • Recent insider selling, including a significant transaction by CEO Kevin Lobo, may raise concerns about the company's future performance and management's confidence in its stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$149.21 billion
P/E Ratio
50.44
Consensus Rating
Moderate Buy
Consensus Price Target
$420.68 (+7.5% Upside)
Volume
1.03 million shares
Average Volume
1.49 million shares
Today's Range
$390.61
$397.23
50-Day Range
$355.17
$399.83
52-Week Range
$314.93
$406.19
Dividend Yield
0.86%
Pfizer stock logo

16. Pfizer NYSE:PFE

$25.76 -0.07 (-0.29%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$25.80 +0.04 (+0.17%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. has a strong market capitalization of $151.79 billion, indicating a robust financial position and the ability to invest in research and development.
  • The stock is currently trading at $26.79, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Recent institutional investments show confidence in Pfizer Inc., with significant increases in holdings from firms like State Street Corp and Charles Schwab Investment Management, suggesting positive market sentiment.

Cons of Pfizer

  • Several analysts have recently lowered their target prices for Pfizer Inc., with firms like Truist Financial and Guggenheim reducing their estimates, which may indicate concerns about future performance.
  • The stock has a relatively high P/E ratio of 36.20, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Pfizer Inc. has a debt-to-equity ratio of 0.63, which, while manageable, indicates that the company does carry some debt, potentially impacting financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.38 billion
P/E Ratio
18.27
Consensus Rating
Moderate Buy
Consensus Price Target
$31.92 (+23.9% Upside)
Volume
36.40 million shares
Average Volume
37.58 million shares
Today's Range
$25.53
$25.96
50-Day Range
$25.23
$27.12
52-Week Range
$24.48
$31.54
Dividend Yield
6.66%
Sanofi stock logo

17. Sanofi NASDAQ:SNY

$53.35 +0.48 (+0.91%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$53.67 +0.32 (+0.60%)
As of 09:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi recently reported earnings per share of $1.57, significantly exceeding the consensus estimate of $0.22, indicating strong financial performance and effective management.
  • The company has shown a year-over-year revenue increase of 12.3%, demonstrating growth potential and resilience in its business operations.
  • With a current stock price of $52.48, Sanofi is trading near its one-year high of $58.97, suggesting positive market sentiment and potential for further appreciation.

Cons of Sanofi

  • Sanofi's revenue for the latest quarter was $13.44 billion, falling short of analyst estimates of $16.59 billion, which may raise concerns about future growth prospects.
  • The company has a quick ratio of 0.65, which is below 1, indicating potential liquidity issues in meeting short-term obligations without selling inventory.
  • Despite a solid earnings report, the price-to-earnings ratio of 26.28 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$134.18 billion
P/E Ratio
21.43
Consensus Rating
Buy
Consensus Price Target
$60.00 (+12.5% Upside)
Volume
2.33 million shares
Average Volume
2.65 million shares
Today's Range
$53.17
$53.61
50-Day Range
$45.89
$54.34
52-Week Range
$45.22
$58.97
Dividend Yield
2.80%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$469.32 -11.84 (-2.46%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$471.54 +2.23 (+0.47%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated has recently reported strong earnings, with an earnings per share (EPS) of $4.38, surpassing analysts' expectations of $3.61. This indicates robust financial performance and potential for future growth.
  • The stock price of Vertex Pharmaceuticals Incorporated is currently at $482.55, reflecting a 2.6% increase in recent trading. A rising stock price can signal investor confidence and market interest.
  • Analysts have a consensus rating of "Moderate Buy" for Vertex Pharmaceuticals Incorporated, with a target price averaging $502.58. This suggests that many analysts believe the stock has room for growth.

Cons of Vertex Pharmaceuticals

  • Despite recent earnings growth, Vertex Pharmaceuticals Incorporated has a negative net margin of 4.52%, which indicates that the company is currently spending more than it earns, raising concerns about long-term profitability.
  • The stock has a high price-to-earnings (P/E) ratio of -232.00, suggesting that the stock may be overvalued relative to its earnings, which could deter value-focused investors.
  • Vertex Pharmaceuticals Incorporated has experienced fluctuations in analyst ratings, with some firms downgrading their ratings and price targets, which can create uncertainty in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$123.91 billion
P/E Ratio
-235.84
Consensus Rating
Moderate Buy
Consensus Price Target
$502.58 (+7.1% Upside)
Volume
1.19 million shares
Average Volume
1.56 million shares
Today's Range
$468.70
$480.47
50-Day Range
$396.64
$488.44
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Gilead Sciences stock logo

19. Gilead Sciences NASDAQ:GILD

$96.04 -2.00 (-2.04%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$96.30 +0.26 (+0.27%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Gilead Sciences, Inc. reported a strong earnings per share (EPS) of $2.02 for the latest quarter, surpassing the consensus estimate of $1.58 by $0.44. This indicates robust financial performance and potential for future growth.
  • The company achieved a revenue of $7.55 billion during the quarter, exceeding expectations and reflecting a 7.0% increase compared to the same period last year. This growth in revenue can be a positive indicator of the company's market position and product demand.
  • Recent analyst upgrades have been favorable, with Oppenheimer raising the price target to $115.00 and Morgan Stanley upgrading their rating to "overweight." Such endorsements from analysts can boost investor confidence and potentially drive stock prices higher.

Cons of Gilead Sciences

  • The company has a high price-to-earnings (P/E) ratio of 1,088.78, which may suggest that the stock is overvalued compared to its earnings. A high P/E ratio can indicate that investors are expecting high growth rates, which may not materialize.
  • Insider sales have totaled 598,414 shares worth $55,953,200 in the last three months, which could signal a lack of confidence in the company's future performance among those who are most familiar with its operations.
  • Despite recent revenue growth, the net margin is only 0.45%, indicating that the company may be facing challenges in converting revenue into profit. Low margins can be a concern for long-term sustainability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$122.18 billion
P/E Ratio
1,067.11
Consensus Rating
Moderate Buy
Consensus Price Target
$98.39 (+2.4% Upside)
Volume
7.18 million shares
Average Volume
6.87 million shares
Today's Range
$95.90
$98.33
50-Day Range
$89.14
$99.65
52-Week Range
$62.07
$100.51
Dividend Yield
3.14%
Bristol-Myers Squibb stock logo

20. Bristol-Myers Squibb NYSE:BMY

$56.96 -0.47 (-0.81%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$57.11 +0.16 (+0.28%)
As of 09:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which positions the company well in the growing pharmaceutical market.
  • The company has demonstrated significant institutional investor interest, with Valley National Advisers Inc. increasing its stake by 494% recently, indicating confidence in the company's future performance.
  • As of the latest trading session, Bristol-Myers Squibb's stock price is $59.15, reflecting a solid market capitalization of approximately $119.97 billion, which suggests stability and potential for growth.

Cons of Bristol-Myers Squibb

  • The company has a high debt-to-equity ratio of 2.83, which indicates that it relies heavily on debt financing. This could pose risks if the company faces financial difficulties or if interest rates rise.
  • Despite a strong product lineup, the pharmaceutical industry is highly competitive, and Bristol-Myers Squibb may face challenges from generic drugs and new entrants that could impact its market share.
  • The stock has experienced fluctuations, with a twelve-month low of $39.35, suggesting potential volatility that could deter conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$116.46 billion
P/E Ratio
-12.89
Consensus Rating
Hold
Consensus Price Target
$57.86 (+1.6% Upside)
Volume
14.34 million shares
Average Volume
10.36 million shares
Today's Range
$56.19
$57.71
50-Day Range
$55.35
$60.61
52-Week Range
$39.35
$61.10
Dividend Yield
4.32%
Medtronic stock logo

21. Medtronic NYSE:MDT

$90.01 -0.81 (-0.89%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$90.20 +0.18 (+0.20%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc reported a quarterly revenue of $8.40 billion, exceeding analysts' expectations of $8.27 billion, indicating strong financial performance and demand for its medical therapies.
  • The company achieved a net margin of 13.00% and a return on equity of 13.79%, showcasing effective management and profitability, which are attractive metrics for investors looking for stable returns.
  • Medtronic plc recently announced a quarterly dividend of $0.70 per share, translating to an annualized dividend of $2.80 and a yield of approximately 3.05%, providing a steady income stream for investors.

Cons of Medtronic

  • Despite recent positive performance, several analysts have downgraded their price targets for Medtronic plc, indicating a cautious outlook on the stock's future performance.
  • The company's payout ratio stands at 85.63%, which is relatively high and may raise concerns about sustainability in dividend payments, especially if earnings do not grow as expected.
  • Insider selling activity has been noted, with an executive vice president selling 9,850 shares, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$116.46 billion
P/E Ratio
27.53
Consensus Rating
Hold
Consensus Price Target
$95.00 (+5.5% Upside)
Volume
6.35 million shares
Average Volume
6.92 million shares
Today's Range
$89.55
$91.17
50-Day Range
$79.61
$92.45
52-Week Range
$75.96
$93.08
Dividend Yield
3.08%
Elevance Health stock logo

22. Elevance Health NYSE:ELV

$391.23 +0.76 (+0.20%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$391.48 +0.25 (+0.06%)
As of 08:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$90.56 billion
P/E Ratio
15.28
Consensus Rating
Moderate Buy
Consensus Price Target
$517.03 (+32.2% Upside)
Volume
1.08 million shares
Average Volume
1.76 million shares
Today's Range
$389.61
$394.72
50-Day Range
$365.83
$411.14
52-Week Range
$362.21
$567.26
Dividend Yield
1.67%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$321.95 -2.58 (-0.79%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$322.82 +0.87 (+0.27%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. has a current stock price of $331.15, which reflects a recent increase of 6.1%, indicating positive market sentiment and potential for further growth.
  • The company has received an average rating of "Moderate Buy" from analysts, suggesting confidence in its future performance and stability.
  • Institutional investors own 62.73% of HCA Healthcare, Inc., which often indicates a strong foundation and trust in the company's long-term prospects.

Cons of HCA Healthcare

  • The company has a high debt-to-equity ratio of 69.07, which indicates that it relies heavily on debt financing, potentially increasing financial risk.
  • Recent insider sales, including significant transactions by executives, may raise concerns about their confidence in the company's short-term performance.
  • Despite the positive stock performance, the company's quick ratio of 0.97 suggests that it may struggle to meet short-term liabilities without additional financing.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$82.20 billion
P/E Ratio
14.65
Consensus Rating
Moderate Buy
Consensus Price Target
$385.67 (+19.8% Upside)
Volume
1.53 million shares
Average Volume
1.65 million shares
Today's Range
$321.21
$328.54
50-Day Range
$296.45
$336.93
52-Week Range
$289.98
$417.14
Dividend Yield
0.81%
The Cigna Group stock logo

24. The Cigna Group NYSE:CI

$286.67 -0.56 (-0.19%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$290.75 +4.08 (+1.42%)
As of 08:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The Cigna Group recently increased its quarterly dividend to $1.51, up from $1.40, indicating a commitment to returning value to shareholders. This represents an annualized dividend of $6.04, providing a yield of 2.05%, which can be attractive for income-focused investors.
  • The current stock price is $293.99, reflecting a recent increase of $11.01 during trading. This upward movement may suggest positive market sentiment and potential for further growth.
  • The company has a strong market capitalization of $81.77 billion, which positions it well within the industry and provides stability for investors.

Cons of The Cigna Group

  • The Cigna Group reported earnings per share of $6.64, missing analysts' consensus estimates of $7.84 by $1.20, which may raise concerns about its ability to meet growth expectations.
  • The company has a net margin of only 1.31%, suggesting that profitability may be under pressure, which could impact future earnings and dividends.
  • With a debt-to-equity ratio of 0.71, The Cigna Group carries a moderate level of debt, which could pose risks in a rising interest rate environment or economic downturn.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.89 billion
P/E Ratio
23.42
Consensus Rating
Buy
Consensus Price Target
$373.69 (+30.4% Upside)
Volume
1.27 million shares
Average Volume
1.95 million shares
Today's Range
$285.27
$289.71
50-Day Range
$265.51
$337.14
52-Week Range
$262.03
$370.83
Dividend Yield
1.95%
Regeneron Pharmaceuticals stock logo

25. Regeneron Pharmaceuticals NASDAQ:REGN

$710.00 -12.07 (-1.67%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$714.68 +4.68 (+0.66%)
As of 09:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is $672.98, which is significantly lower than its 12-month high of $1,211.20, indicating potential for price recovery and growth.
  • Regeneron Pharmaceuticals, Inc. has a strong market capitalization of $73.95 billion, suggesting stability and a solid position in the biopharmaceutical industry.
  • The company boasts a low debt-to-equity ratio of 0.09, indicating a strong balance sheet and lower financial risk, which is attractive to investors seeking stability.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced a significant decline from its 12-month high, which may indicate underlying issues or market volatility that could deter potential investors.
  • Barclays recently lowered their price objective for the stock from $1,080.00 to $1,065.00, which may reflect concerns about the company's near-term performance.
  • Despite a strong market cap, the price-to-earnings (P/E) ratio of 16.65 may suggest that the stock is overvalued compared to its earnings, which could be a red flag for value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.35 billion
P/E Ratio
18.55
Consensus Rating
Moderate Buy
Consensus Price Target
$973.13 (+37.1% Upside)
Volume
885,523 shares
Average Volume
978,359 shares
Today's Range
$709.55
$731.42
50-Day Range
$666.85
$788.00
52-Week Range
$642.00
$1,211.20
Dividend Yield
N/A
Zoetis stock logo

26. Zoetis NYSE:ZTS

$171.37 -2.75 (-1.58%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$172.74 +1.37 (+0.80%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. has shown strong financial performance, reporting a revenue of $2.40 billion for the latest quarter, exceeding analysts' expectations of $2.29 billion. This indicates robust demand for its products and effective management.
  • The company recently increased its quarterly dividend from $0.43 to $0.50, reflecting a commitment to returning value to shareholders. This represents an annualized dividend of $2.00, providing a yield of 1.17%, which can be attractive for income-focused investors.
  • Analysts have a consensus rating of "Buy" for Zoetis Inc., with a target price averaging $215.00. This suggests potential upside for investors based on current market conditions.

Cons of Zoetis

  • Despite strong performance, the stock has recently traded down $1.90, indicating potential volatility and market concerns that could affect short-term investment returns.
  • The company has a debt-to-equity ratio of 1.26, which suggests that it has a relatively high level of debt compared to its equity. This could pose risks, especially in a rising interest rate environment.
  • Some analysts have lowered their price targets for Zoetis Inc., with Stifel Nicolaus reducing their target from $210.00 to $180.00. This could indicate a more cautious outlook on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.56 billion
P/E Ratio
32.21
Consensus Rating
Buy
Consensus Price Target
$215.00 (+25.5% Upside)
Volume
1.93 million shares
Average Volume
2.58 million shares
Today's Range
$170.93
$175.50
50-Day Range
$162.24
$178.84
52-Week Range
$144.80
$200.53
Dividend Yield
1.15%
McKesson stock logo

27. McKesson NYSE:MCK

$595.77 -3.98 (-0.66%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$598.00 +2.24 (+0.38%)
As of 09:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • Recent earnings report showed an EPS of $7.07, exceeding expectations of $6.88, indicating strong financial performance.
  • Revenue for the latest quarter was $93.65 billion, surpassing analyst estimates of $89.33 billion, reflecting robust growth.
  • Analysts have a consensus rating of "Moderate Buy" with a target price of $646.14, suggesting potential for price appreciation.

Cons of McKesson

  • Negative return on equity of 207.50% suggests that the company is not effectively generating profit from its equity, which could be a red flag for investors.
  • Net margin of only 0.77% indicates that the company has a low profitability level, which may limit its ability to weather economic downturns.
  • Recent insider selling, with an executive selling shares at an average price of $572.79, could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.13 billion
P/E Ratio
27.28
Consensus Rating
Moderate Buy
Consensus Price Target
$645.79 (+8.4% Upside)
Volume
715,172 shares
Average Volume
765,241 shares
Today's Range
$591.13
$603.21
50-Day Range
$562.79
$621.39
52-Week Range
$464.42
$637.51
Dividend Yield
0.47%
GSK stock logo

28. GSK NYSE:GSK

$36.03 -0.35 (-0.96%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$36.34 +0.31 (+0.86%)
As of 09:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc has a current stock price of $34.29, which is significantly lower than the consensus target price of $43.25, indicating potential for price appreciation.
  • The company recently increased its quarterly dividend to $0.3928, representing an annualized dividend of $1.57 and a yield of 4.58%. This increase reflects GSK's commitment to returning value to shareholders.
  • GSK has a market capitalization of $71.06 billion, which suggests a stable and established presence in the pharmaceutical industry, potentially providing a safer investment compared to smaller companies.

Cons of GSK

  • GSK has experienced recent downgrades from multiple analysts, including a shift from "buy" to "hold" ratings, which may indicate a lack of confidence in the stock's short-term performance.
  • The company has a high dividend payout ratio of 95.45%, which suggests that a large portion of its earnings is being distributed to shareholders. This could limit the funds available for reinvestment in growth opportunities.
  • GSK's stock has a 12-month high of $45.92, which may indicate that it is currently trading closer to its peak, potentially limiting upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$75.40 billion
P/E Ratio
22.66
Consensus Rating
Moderate Buy
Consensus Price Target
$43.25 (+20.0% Upside)
Volume
5.36 million shares
Average Volume
4.88 million shares
Today's Range
$35.97
$36.52
50-Day Range
$32.12
$37.67
52-Week Range
$31.72
$45.92
Dividend Yield
4.06%
CVS Health stock logo

29. CVS Health NYSE:CVS

$53.95 -0.29 (-0.53%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$54.19 +0.24 (+0.44%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has a strong market capitalization of approximately $70.72 billion, indicating a robust presence in the healthcare sector, which can provide stability and growth potential for investors.
  • The company recently reported earnings per share (EPS) of $1.09, exceeding analysts' expectations, which reflects strong operational performance and can lead to increased investor confidence.
  • CVS Health Co. has a current stock price of $56.39, which is considered attractive given its potential for growth, especially with a consensus target price of $68.12 from analysts.

Cons of CVS Health

  • Despite recent positive earnings, CVS Health Co. has faced a decline in price targets from various analysts, indicating potential concerns about future performance.
  • The company's debt-to-equity ratio stands at 0.80, which, while manageable, suggests that CVS Health Co. has a significant amount of debt relative to its equity, potentially increasing financial risk.
  • CVS Health Co. has a quick ratio of 0.59, which indicates that the company may struggle to meet its short-term liabilities without selling inventory, raising liquidity concerns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$68.26 billion
P/E Ratio
13.69
Consensus Rating
Moderate Buy
Consensus Price Target
$68.12 (+26.3% Upside)
Volume
5.91 million shares
Average Volume
12.15 million shares
Today's Range
$53.90
$54.81
50-Day Range
$43.78
$59.20
52-Week Range
$43.56
$80.75
Dividend Yield
4.90%
Becton, Dickinson and Company stock logo

30. Becton, Dickinson and Company NYSE:BDX

$230.22 +3.01 (+1.33%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$230.00 -0.22 (-0.10%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company reported a quarterly earnings per share (EPS) of $3.81, exceeding the consensus estimate of $3.77, indicating strong financial performance and effective management.
  • Becton, Dickinson and Company has shown a year-over-year revenue growth of 6.9%, reflecting its ability to expand and capture market share in the medical supplies sector.
  • The current stock price is approximately $240.00, which is considered attractive given the company's solid fundamentals and growth prospects.

Cons of Becton, Dickinson and Company

  • The quick ratio of 0.74 indicates that the company may face challenges in meeting its short-term liabilities, which could raise concerns about liquidity.
  • Insider selling activity has been noted, with executives selling a total of 9,844 shares worth over $2.2 million in the last 90 days, which may signal a lack of confidence in the stock's future performance.
  • The dividend payout ratio (DPR) is at 70.03%, which is relatively high and could limit the company's ability to reinvest in growth opportunities or respond to market changes.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$65.89 billion
P/E Ratio
38.24
Consensus Rating
Buy
Consensus Price Target
$283.00 (+22.9% Upside)
Volume
3.78 million shares
Average Volume
2.20 million shares
Today's Range
$226.55
$230.85
50-Day Range
$220.02
$249.75
52-Week Range
$218.75
$251.99
Dividend Yield
1.83%
Cencora stock logo

31. Cencora NYSE:COR

$247.94 +1.81 (+0.74%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$247.84 -0.10 (-0.04%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Market Capitalization
$47.57 billion
P/E Ratio
35.27
Consensus Rating
Moderate Buy
Consensus Price Target
$277.90 (+12.1% Upside)
Volume
3.82 million shares
Average Volume
1.33 million shares
Today's Range
$244.75
$249.47
50-Day Range
$224.68
$258.54
52-Week Range
$214.77
$262.26
Dividend Yield
0.89%
Alcon stock logo

32. Alcon NYSE:ALC

$89.50 -2.15 (-2.35%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$90.43 +0.93 (+1.04%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Alcon Inc. has shown a strong fifty-two week performance of 26.72%, indicating a positive trend in its stock price over the past year, which can attract investors looking for growth.
  • The current stock price is $85.13, which may be considered a reasonable entry point for investors looking to capitalize on potential future growth.
  • Institutional ownership stands at 72.64%, suggesting that a significant portion of the company is held by institutional investors, which can indicate confidence in the company's future prospects.

Cons of Alcon

  • There has been a month-to-month decrease in shares shorted, from 3,160,000 to 3,130,000, which may suggest a lack of momentum or interest from short sellers, potentially indicating a lack of confidence in the stock's upward movement.
  • The company has a relatively high number of outstanding shares at 499,700,000, which can dilute earnings per share and may affect the stock's price appreciation potential.
  • Despite a positive performance, the month-to-month change in shares shorted shows a slight decrease of 0.95%, which could indicate a potential slowdown in investor interest.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.21 billion
P/E Ratio
38.25
Consensus Rating
Moderate Buy
Consensus Price Target
$102.38 (+14.4% Upside)
Volume
1.25 million shares
Average Volume
1.28 million shares
Today's Range
$89.42
$91.57
50-Day Range
$82.70
$93.55
52-Week Range
$74.53
$101.10
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

33. Takeda Pharmaceutical NYSE:TAK

$13.54 -0.07 (-0.51%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$13.48 -0.06 (-0.44%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited has shown significant institutional interest, with major investors like Crossmark Global Holdings Inc. increasing their holdings by 284.9% recently, indicating strong confidence in the company's future performance.
  • The current stock price is $12.95, which may present a buying opportunity for investors looking for value in the pharmaceutical sector, especially given the company's market capitalization of approximately $41.19 billion.
  • Takeda Pharmaceutical Company Limited has a solid financial foundation, with a debt-to-equity ratio of 0.64, suggesting that the company is not overly reliant on debt to finance its operations, which can be a positive indicator for long-term stability.

Cons of Takeda Pharmaceutical

  • Despite recent institutional investments, the stock has experienced a decline of 0.8% recently, which may indicate volatility and uncertainty in the market.
  • The company has a relatively high price-to-earnings-growth (PEG) ratio of 0.23, which, while lower than the P/E ratio, suggests that growth expectations may not be fully realized, potentially leading to disappointing returns.
  • Takeda Pharmaceutical Company Limited's stock has a 1-year low of $12.57, indicating that it has faced challenges in maintaining its stock price above this threshold, which could be a concern for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.31 billion
P/E Ratio
33.85
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
1.47 million shares
Average Volume
1.94 million shares
Today's Range
$13.52
$13.62
50-Day Range
$12.91
$13.93
52-Week Range
$12.57
$15.08
Dividend Yield
3.93%
Haleon stock logo

34. Haleon NYSE:HLN

$9.54 +0.04 (+0.37%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$9.65 +0.11 (+1.10%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Haleon plc has recently been upgraded to a "strong-buy" rating by UBS Group, indicating strong confidence from analysts in the company's future performance.
  • The stock is currently trading at $9.24, which is above its 1-year low of $7.89, suggesting a potential for growth as it approaches its 1-year high of $10.80.
  • Institutional investors, including Park Avenue Securities LLC and Clarius Group LLC, have significantly increased their holdings in Haleon plc, reflecting positive sentiment and confidence in the company's prospects.

Cons of Haleon

  • Despite recent upgrades, some analysts have downgraded Haleon from "outperform" to "market perform," indicating a more cautious outlook on the stock's performance.
  • Haleon plc's stock has experienced volatility, with significant fluctuations in trading prices, which may pose risks for investors seeking stability.
  • Only 6.67% of the company's stock is owned by institutional investors, which may suggest a lack of widespread confidence among larger investment firms.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.05 billion
P/E Ratio
28.07
Consensus Rating
Moderate Buy
Consensus Price Target
$10.95 (+14.7% Upside)
Volume
7.83 million shares
Average Volume
12.35 million shares
Today's Range
$9.52
$9.58
50-Day Range
$9.02
$9.93
52-Week Range
$7.89
$10.80
Dividend Yield
1.11%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$70.38 -0.61 (-0.86%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$70.14 -0.24 (-0.34%)
As of 08:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported a strong net margin of 70.82%, indicating high profitability relative to its revenue, which can be attractive for investors seeking companies with solid financial health.
  • Edwards Lifesciences Co. has a market capitalization of $40.82 billion, suggesting it is a well-established player in the medical research sector, which can provide stability for investors.
  • With a current stock price of $69.21, the shares are trading below their 52-week high of $96.12, potentially offering a buying opportunity for investors looking for growth as the stock may rebound.

Cons of Edwards Lifesciences

  • The company reported revenue of $1.35 billion for the latest quarter, which fell short of analyst estimates of $1.57 billion, indicating potential challenges in meeting market expectations.
  • Insider selling activity has been noted, with significant shares sold recently, which could signal a lack of confidence from those closest to the company.
  • The price-to-earnings ratio of 9.99, while seemingly low, may suggest that the stock is undervalued, but it could also indicate that investors are cautious about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.87 billion
P/E Ratio
10.16
Consensus Rating
Hold
Consensus Price Target
$79.19 (+12.5% Upside)
Volume
3.70 million shares
Average Volume
4.44 million shares
Today's Range
$70.32
$71.68
50-Day Range
$68.95
$75.92
52-Week Range
$58.93
$96.12
Dividend Yield
N/A
Agilent Technologies stock logo

36. Agilent Technologies NYSE:A

$145.21 -2.44 (-1.65%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$146.11 +0.91 (+0.62%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. recently reported quarterly earnings of $1.46 per share, exceeding analysts' expectations of $1.41, indicating strong financial performance and effective management.
  • The company has shown a year-over-year revenue increase of 0.8%, with revenues reaching $1.70 billion, suggesting consistent demand for its products and services in the life sciences and diagnostics sectors.
  • Agilent Technologies, Inc. has a solid return on equity of 25.43%, which reflects its ability to generate profit from shareholders' equity, a positive indicator for potential investors.

Cons of Agilent Technologies

  • Despite the recent earnings beat, the stock has been rated with a mix of hold and buy ratings, with one analyst issuing a sell rating, indicating some uncertainty in market sentiment.
  • Analysts have varied opinions on the stock price, with some lowering their price targets, such as Barclays reducing it from $145.00 to $135.00, which may suggest potential downward pressure on the stock.
  • The company has a relatively high P/E ratio of 32.75, which could indicate that the stock is overvalued compared to its earnings, making it a riskier investment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.43 billion
P/E Ratio
32.85
Consensus Rating
Moderate Buy
Consensus Price Target
$144.38 (-0.6% Downside)
Volume
1.56 million shares
Average Volume
1.73 million shares
Today's Range
$144.41
$149.39
50-Day Range
$133.01
$152.87
52-Week Range
$124.16
$155.35
Dividend Yield
0.67%
GE HealthCare Technologies stock logo

37. GE HealthCare Technologies NASDAQ:GEHC

$87.64 -0.91 (-1.03%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$88.79 +1.15 (+1.31%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported earnings per share (EPS) of $1.14, exceeding analysts' expectations of $1.06, indicating strong financial performance.
  • GE HealthCare Technologies Inc. has a current stock price of $88.25, which is below the average target price of $96.00 set by analysts, suggesting potential for price appreciation.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with several upgrades in target prices, reflecting positive sentiment in the market.

Cons of GE HealthCare Technologies

  • The stock has experienced a recent decline of 1.5%, which may indicate volatility and potential risks in the short term.
  • Insider ownership is relatively low at 0.27%, which could suggest a lack of confidence from those closest to the company.
  • The company has a debt-to-equity ratio of 1.12, indicating that it has a significant amount of debt compared to its equity, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.46 billion
P/E Ratio
24.08
Consensus Rating
Moderate Buy
Consensus Price Target
$96.00 (+9.5% Upside)
Volume
1.67 million shares
Average Volume
2.37 million shares
Today's Range
$87.50
$89.36
50-Day Range
$77.09
$89.55
52-Week Range
$74.51
$94.55
Dividend Yield
0.16%
argenx stock logo

38. argenx NASDAQ:ARGX

$646.64 -11.33 (-1.72%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$654.00 +7.36 (+1.14%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • argenx SE's lead product candidate, efgartigimod, is showing promise in treating multiple autoimmune diseases, which could lead to significant market opportunities and revenue growth.
  • Recent upgrades from several brokerages, including a price target increase to $706.00, indicate strong market confidence in the company's future performance.
  • The current stock price is $621.29, reflecting a healthy trading volume and investor interest, suggesting a favorable entry point for potential investors.

Cons of argenx

  • Despite positive developments, the biotechnology sector can be highly volatile, and any setbacks in clinical trials or regulatory approvals could negatively impact stock performance.
  • With a consensus rating of "Moderate Buy," there may be a lack of overwhelming bullish sentiment, which could limit short-term price appreciation.
  • The company faces competition from other biotechnology firms developing similar therapies, which could affect market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.98 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$658.39 (+1.8% Upside)
Volume
228,947 shares
Average Volume
282,116 shares
Today's Range
$646.61
$658.46
50-Day Range
$603.40
$671.74
52-Week Range
$349.86
$678.21
Dividend Yield
N/A
Veeva Systems stock logo

39. Veeva Systems NYSE:VEEV

$237.16 -2.27 (-0.95%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$239.15 +2.00 (+0.84%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Veeva Systems Inc. has received multiple upgrades from analysts, with price targets raised significantly, indicating strong market confidence. For instance, Piper Sandler increased their price target from $280.00 to $290.00, suggesting potential for growth.
  • The current stock price of Veeva Systems Inc. is $223.23, which is near its 52-week low of $170.25, presenting a potential buying opportunity for investors looking for value.
  • Veeva Systems Inc. has a solid market capitalization of $36.24 billion, which reflects its stability and ability to invest in growth opportunities within the life sciences sector.

Cons of Veeva Systems

  • Veeva Systems Inc. was recently downgraded from a "buy" to a "hold" rating by StockNews.com, which may indicate a potential slowdown in growth or performance expectations.
  • The stock has experienced significant insider selling, with key executives reducing their holdings, which could signal a lack of confidence in the company's short-term prospects.
  • Despite a strong market position, Veeva Systems Inc. has a high P/E ratio of 55.12, suggesting that the stock may be overvalued relative to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.87 billion
P/E Ratio
58.56
Consensus Rating
Moderate Buy
Consensus Price Target
$253.96 (+7.1% Upside)
Volume
714,333 shares
Average Volume
1.00 million shares
Today's Range
$235.42
$240.49
50-Day Range
$210.25
$250.45
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
IQVIA stock logo

40. IQVIA NYSE:IQV

$208.13 -1.83 (-0.87%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$209.24 +1.12 (+0.54%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. has received multiple "overweight" ratings from analysts, indicating strong confidence in the company's growth potential and performance.
  • The current stock price is $207.06, which is significantly lower than the consensus price target of $255.71, suggesting potential for price appreciation.
  • Institutional ownership is high, with 89.62% of the stock held by institutional investors and hedge funds, which often indicates stability and confidence in the company's future.

Cons of IQVIA

  • Recent price target reductions by analysts, such as JPMorgan lowering their target from $279.00 to $240.00, may indicate concerns about the company's near-term performance.
  • The stock has experienced volatility, with a one-year high of $261.73 and a low of $187.62, which could pose risks for investors looking for stable returns.
  • Despite a majority of buy ratings, there are still four analysts who have rated the stock as a hold, suggesting that some experts are cautious about its current valuation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.11 billion
P/E Ratio
27.75
Consensus Rating
Moderate Buy
Consensus Price Target
$252.39 (+21.3% Upside)
Volume
1.75 million shares
Average Volume
1.45 million shares
Today's Range
$205.41
$211.67
50-Day Range
$190.97
$209.76
52-Week Range
$187.62
$261.73
Dividend Yield
N/A
IDEXX Laboratories stock logo

41. IDEXX Laboratories NASDAQ:IDXX

$459.78 -0.78 (-0.17%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$460.40 +0.62 (+0.13%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • IDEXX Laboratories, Inc. recently reported earnings per share of $2.80, exceeding the consensus estimate of $2.69, indicating strong financial performance and effective management.
  • The company has a robust return on equity of 55.42%, showcasing its ability to generate profit from shareholders' equity, which is a positive sign for potential investors.
  • With a current stock price of $435.33, IDEXX Laboratories, Inc. has shown resilience in the market, reflecting investor confidence and potential for future growth.

Cons of IDEXX Laboratories

  • The stock has experienced a decline from its 1-year high of $583.39, which may indicate volatility and potential challenges in maintaining its previous performance levels.
  • Recent revenue of $975.50 million fell short of the consensus estimate of $980.32 million, suggesting that the company may face difficulties in meeting market expectations.
  • The P/E ratio of 41.98 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.71 billion
P/E Ratio
43.09
Consensus Rating
Moderate Buy
Consensus Price Target
$524.38 (+14.0% Upside)
Volume
624,575 shares
Average Volume
753,210 shares
Today's Range
$457.35
$468.80
50-Day Range
$408.85
$469.04
52-Week Range
$398.50
$583.39
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

42. Alnylam Pharmaceuticals NASDAQ:ALNY

$276.19 -2.06 (-0.74%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$278.10 +1.91 (+0.69%)
As of 09:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance. Notably, Canaccord Genuity Group recently raised their price objective to $384.00, suggesting significant upside potential.
  • The current stock price is $275.54, which is well above its one-year low of $141.98, indicating a recovery and potential for further growth.
  • Institutional investors own approximately 92.97% of Alnylam Pharmaceuticals, Inc.'s stock, reflecting strong institutional confidence and support for the company's long-term prospects.

Cons of Alnylam Pharmaceuticals

  • The company reported a loss of $0.87 earnings per share (EPS) in its latest quarterly earnings, which was below the consensus estimate, indicating potential challenges in profitability.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio of 31.64, suggesting that the company is heavily reliant on debt financing, which can be risky if market conditions change.
  • Despite a strong institutional backing, there is one analyst rating the stock as a sell, which could indicate concerns about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.89 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$298.61 (+8.1% Upside)
Volume
469,011 shares
Average Volume
695,622 shares
Today's Range
$272.35
$278.03
50-Day Range
$233.15
$278.99
52-Week Range
$141.98
$304.39
Dividend Yield
N/A
ResMed stock logo

43. ResMed NYSE:RMD

$236.84 -0.34 (-0.14%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$238.52 +1.68 (+0.71%)
As of 08:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. reported a strong quarterly earnings result with an EPS of $2.20, surpassing analysts' expectations of $2.03, indicating robust financial performance and effective management.
  • The company has shown a year-over-year revenue growth of 11.1%, reaching $1.22 billion, which reflects its ability to expand and capture market share in the healthcare sector.
  • With a current stock price around $248.81, ResMed Inc. is positioned within a healthy market cap of $36.75 billion, suggesting stability and potential for growth.

Cons of ResMed

  • Insider selling has been observed, with directors selling a total of 11,099 shares valued at $2,719,385 over the last quarter, which may signal a lack of confidence in the stock's future performance.
  • The stock has a relatively high PE ratio of 33.15, which could indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite recent revenue growth, the company posted a lower EPS of $1.64 in the same quarter last year, which may raise concerns about sustainability in earnings growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.83 billion
P/E Ratio
27.96
Consensus Rating
Moderate Buy
Consensus Price Target
$244.73 (+3.3% Upside)
Volume
830,561 shares
Average Volume
1.06 million shares
Today's Range
$235.63
$239.07
50-Day Range
$228.48
$257.63
52-Week Range
$170.56
$263.05
Dividend Yield
0.89%
DexCom stock logo

44. DexCom NASDAQ:DXCM

$88.08 -0.24 (-0.27%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$88.68 +0.59 (+0.68%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • Recent institutional investments indicate strong confidence in DexCom, Inc., with Merit Financial Group LLC acquiring a stake valued at approximately $228,000 and Avanza Fonder AB purchasing shares worth about $3,731,000.
  • The stock has shown resilience, currently trading at $87.53, reflecting a solid market position despite fluctuations.
  • DexCom, Inc. has a significant institutional ownership of 97.75%, suggesting that many professional investors believe in the company's long-term potential.

Cons of DexCom

  • The stock has experienced a decline of 1.4% recently, which may indicate volatility and potential challenges in maintaining its market value.
  • With a price-to-earnings ratio of 50.53, the stock may be considered overvalued compared to its earnings, suggesting that investors could be paying a premium for future growth that may not materialize.
  • The company has a debt-to-equity ratio of 1.23, which indicates that it has taken on a significant amount of debt relative to its equity, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.50 billion
P/E Ratio
52.74
Consensus Rating
Moderate Buy
Consensus Price Target
$98.41 (+11.7% Upside)
Volume
2.93 million shares
Average Volume
3.36 million shares
Today's Range
$87.60
$88.72
50-Day Range
$75.26
$88.78
52-Week Range
$62.34
$142.00
Dividend Yield
N/A
Humana stock logo

45. Humana NYSE:HUM

$274.06 -5.52 (-1.97%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$273.18 -0.88 (-0.32%)
As of 09:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price of Humana Inc. is $294.47, reflecting a recent increase of 0.2%, which may indicate positive market sentiment.
  • Humana Inc. reported earnings per share of $4.16 for the latest quarter, surpassing the consensus estimate of $3.48 by $0.68, showcasing strong financial performance.
  • The company has a market capitalization of $35.46 billion, indicating a significant size and stability in the insurance sector.

Cons of Humana

  • The stock has a price-to-earnings (P/E) ratio of 26.08, which may be considered high, suggesting that the stock could be overvalued compared to its earnings.
  • Humana Inc. has a price-to-earnings-growth (PEG) ratio of 2.15, indicating that the stock's price may not be justified by its earnings growth rate, which could deter value-focused investors.
  • The company has experienced a fifty-two week high of $406.46, which may indicate that the stock is currently trading at a lower price compared to its peak, raising concerns about potential volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.66 billion
P/E Ratio
24.27
Consensus Rating
Hold
Consensus Price Target
$297.68 (+8.6% Upside)
Volume
984,762 shares
Average Volume
1.52 million shares
Today's Range
$273.21
$281.54
50-Day Range
$233.89
$303.57
52-Week Range
$213.31
$406.46
Dividend Yield
1.27%
Cardinal Health stock logo

46. Cardinal Health NYSE:CAH

$127.62 +0.57 (+0.45%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$128.26 +0.64 (+0.50%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. has received multiple upgrades from analysts, with recent price targets raised to as high as $139.00, indicating strong market confidence in the company's growth potential.
  • The stock is currently trading at $128.89, which is close to its twelve-month high of $129.68, suggesting strong performance and investor interest.
  • Cardinal Health, Inc. reported earnings per share of $1.88, exceeding analyst expectations, which reflects the company's ability to generate profits effectively.

Cons of Cardinal Health

  • The company experienced a revenue decline of 4.3% year-over-year, which may raise concerns about its growth trajectory and market competitiveness.
  • Cardinal Health, Inc. has a negative return on equity of 56.56%, indicating that the company is not effectively generating profits from its equity, which could deter potential investors.
  • Despite recent upgrades, the stock has a relatively high P/E ratio of 25.08, which may suggest that it is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.69 billion
P/E Ratio
23.81
Consensus Rating
Moderate Buy
Consensus Price Target
$136.87 (+7.2% Upside)
Volume
1.80 million shares
Average Volume
2.33 million shares
Today's Range
$126.62
$128.45
50-Day Range
$115.81
$130.65
52-Week Range
$93.17
$132.84
Dividend Yield
1.59%
Centene stock logo

47. Centene NYSE:CNC

$58.95 +0.32 (+0.55%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$59.13 +0.18 (+0.31%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Recent insider buying indicates confidence in the company's future. The CFO acquired shares at an average cost of $58.14, suggesting belief in the stock's potential for growth.
  • Analysts have a generally positive outlook, with an average rating of "Moderate Buy" and a target price of $80.92, indicating potential upside from the current stock price of $61.72.
  • Centene Co. has a strong market capitalization of approximately $31.16 billion, which reflects its stability and ability to invest in growth opportunities.

Cons of Centene

  • Recent downgrades from analysts, including a reduction in target prices by Jefferies Financial Group and Stephens, may indicate concerns about the company's short-term performance.
  • Insider ownership is relatively low, with only 0.33% of the stock owned by insiders, which could suggest a lack of alignment between management and shareholder interests.
  • The stock has experienced volatility, with a 52-week range between $55.03 and $81.42, indicating potential risks associated with price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.60 billion
P/E Ratio
9.45
Consensus Rating
Moderate Buy
Consensus Price Target
$81.31 (+37.9% Upside)
Volume
3.38 million shares
Average Volume
4.20 million shares
Today's Range
$58.30
$59.28
50-Day Range
$56.71
$65.88
52-Week Range
$55.03
$81.42
Dividend Yield
N/A
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$117.61 -2.33 (-1.94%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$119.40 +1.79 (+1.52%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • BioNTech SE reported a significant earnings per share (EPS) of $0.81 for the latest quarter, surpassing analysts' expectations of a loss of $1.26 by $2.07, indicating strong financial performance.
  • The company achieved a remarkable revenue of $1.24 billion during the quarter, which is substantially higher than the anticipated $514.08 million, showcasing robust business growth.
  • Year-over-year revenue growth of 38.9% demonstrates BioNTech SE's ability to expand its market presence and increase sales effectively.

Cons of BioNTech

  • BioNTech SE has a negative net margin of 15.16%, indicating that the company is currently not profitable, which could be a concern for potential investors.
  • The company also has a negative return on equity of 2.35%, suggesting that it is not generating a positive return for its shareholders, which may deter investment.
  • Analysts forecast a negative EPS of -3.72 for the current year, indicating expectations of continued financial challenges ahead.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.75 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$142.72 (+21.3% Upside)
Volume
416,114 shares
Average Volume
687,867 shares
Today's Range
$117.49
$120.18
50-Day Range
$111.34
$126.88
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$1,390.00 +32.74 (+2.41%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$1,390.10 +0.11 (+0.01%)
As of 07:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The company reported earnings per share (EPS) of $10.21, exceeding the consensus estimate of $10.00, indicating strong financial performance.
  • Mettler-Toledo International Inc. has a market capitalization of $28.81 billion, suggesting it is a well-established player in the precision instruments market.
  • Analysts have a consensus target price of $1,351.25, which is above the current stock price, indicating potential for price appreciation.

Cons of Mettler-Toledo International

  • The stock has a relatively high P/E ratio of 36.81, which may indicate that it is overvalued compared to its earnings.
  • Insider ownership is only 1.94%, which may suggest a lack of confidence from those closest to the company.
  • Wells Fargo & Company recently reduced their target price from $1,400.00 to $1,350.00, indicating some analysts may have concerns about future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.64 billion
P/E Ratio
34.30
Consensus Rating
Hold
Consensus Price Target
$1,351.25 (-2.8% Downside)
Volume
461,136 shares
Average Volume
114,468 shares
Today's Range
$1,357.17
$1,438.46
50-Day Range
$1,206.02
$1,390.00
52-Week Range
$1,133.46
$1,546.93
Dividend Yield
N/A
Koninklijke Philips stock logo

50. Koninklijke Philips NYSE:PHG

$27.30 -0.15 (-0.53%)
Closing price 02/7/2025 03:59 PM Eastern
Extended Trading
$27.61 +0.31 (+1.12%)
As of 09:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • Current stock price is $26.55, showing a recent increase, which may indicate positive market sentiment and potential for further growth.
  • Institutional ownership is at 13.67%, suggesting that many large investors have confidence in the company's future performance.
  • Recent upgrades from analysts, such as Jefferies Financial Group raising the rating from "underperform" to "hold," indicate a more favorable outlook for the stock.

Cons of Koninklijke Philips

  • High debt-to-equity ratio of 0.60, which may indicate that the company is relying on debt to finance its operations, potentially increasing financial risk.
  • Negative P/E ratio of -63.21, suggesting that the company is currently not profitable, which could deter potential investors.
  • Recent decrease in shares held by Bonness Enterprises Inc. by 15.2%, indicating a lack of confidence from some institutional investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.80 billion
P/E Ratio
-65.01
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
702,523 shares
Average Volume
602,377 shares
Today's Range
$27.25
$27.73
50-Day Range
$24.71
$28.07
52-Week Range
$19.55
$32.91
Dividend Yield
3.33%